Recap
A good deal - faster. With enhanced content, analytics and visualization tools.
Already a Customer
Description:
Whether you are looking to buy, sell, or license a drug candidate, our gold standard biopharma deals intelligence has the insight to support your deals. Thomson Reuters Recap offers you rapid insight into critical deal making trends and allows you to uncover nuances in specific deal types.
Recap clients include biotechnology and pharmaceutical companies, universities, investment banking, and venture firms. More than 1,500 organizations utilize Recap’s data services. Recap combines extensive deals analysis experience with the breadth of Life Sciences service offerings from Thomson Reuters creating a powerful combination for clients.
In addition to the powerful deal data that is provided as part of your Recap subscription, a variety of tools that provide intuitive visualizations and analytics are available with the subscription or as an add-on product: Deal Builder, Deal Builder Select, Valuation Analyzer and Development Optimizer.
Features
- Over 40,000 deal records that are updated daily, including press releases, SEC filed contracts, and clinical trials data.
- Unredacted contracts, acquired through FOIA requests, give you a complete view into the commercial details including post commercialization royalty rates.
- Intuitive interface and superior analytics enabling you to quickly make informed decisions based on data that is highly specific to your needs.
Benefits
- Determine how much an asset is worth
- Evaluate the right time to license your asset in the drug development process
- Locate potential partnership opportunities and conduct due diligence
- Determine which type of transaction is best for you
- Compare market-based deal terms for different types of transactions
- Study and compare attrition and advancement rates and reasons for termination
- Identify potential partners based on development and regulatory performance
- Find critical deal terms from unredacted contracts
- Compare deals to find market rates for royalties, transfer prices, and profit splits
- Identify deal comparables, deal structure alternatives, and critical deal terms